Clinical and Translational Research Center, University at Buffalo, the State University of New York, Buffalo, New York, USA.
Division of Infectious Diseases, Department of Medicine, University at Buffalo, the State University of New York, Buffalo, New York, USA.
Infect Immun. 2018 Feb 20;86(3). doi: 10.1128/IAI.00652-17. Print 2018 Mar.
A vaccine against would reduce tremendous morbidity, mortality, and financial burden by preventing otitis media in children and exacerbations of chronic obstructive pulmonary disease (COPD) in adults. Oligopeptide permease A (OppA) is a candidate vaccine antigen that is (i) a nutritional virulence factor expressed on the bacterial cell surface during infection, (ii) widely conserved among strains, (iii) highly immunogenic, and (iv) a protective antigen based on its capacity to induce protective responses in immunized animals. In the present study, we show that the antibodies to OppA following vaccination mediate accelerated clearance in animals after pulmonary challenge. To identify regions of OppA that bind protective antibodies, truncated constructs of OppA were engineered and studied to map regions of OppA with surface-accessible epitopes that bind high-avidity antibodies following vaccination. Protective epitopes were located in the N and C termini of the protein. Immunization of mice with constructs corresponding to these regions (T5 and T8) induced protective responses. Studies of overlapping peptide libraries of constructs T5 and T8 with OppA immune serum identified two discrete regions on each construct. These potentially protective regions were mapped on a three-dimensional computational model of OppA, where regions with solvent-accessible amino acids were identified as three potentially protective epitopes. In all, these studies revealed two regions with three specific epitopes in OppA that induce potentially protective antibody responses following vaccination. Detection of antibodies to these regions could serve to guide vaccine formulation and as a diagnostic tool for monitoring development of protective responses during clinical trials.
一种针对肺炎链球菌的疫苗可以通过预防儿童中耳炎和成人慢性阻塞性肺疾病(COPD)的恶化,显著减少发病率、死亡率和经济负担。寡肽通透酶 A(OppA)是一种候选疫苗抗原,具有以下特点:(i)在感染过程中表达于细菌细胞表面的营养毒性因子;(ii)在菌株间广泛保守;(iii)高度免疫原性;(iv)基于其在免疫动物中诱导保护反应的能力,是一种保护性抗原。在本研究中,我们表明,接种疫苗后针对 OppA 的抗体介导了动物在肺部挑战后的快速清除。为了鉴定与保护性抗体结合的 OppA 区域,我们构建了 OppA 的截断构建体并进行了研究,以绘制与接种疫苗后结合高亲和力抗体的表面可及表位的 OppA 区域图。保护性表位位于该蛋白的 N 和 C 末端。用这些区域(T5 和 T8)的构建体免疫小鼠可诱导保护性反应。对 T5 和 T8 构建体的重叠肽文库与 OppA 免疫血清进行研究,鉴定了每个构建体上的两个离散区域。这些潜在的保护性区域在 OppA 的三维计算模型上进行了映射,其中具有溶剂可及氨基酸的区域被鉴定为三个潜在的保护性表位。总之,这些研究揭示了 OppA 中具有三个特定表位的两个区域,接种疫苗后可诱导潜在的保护性抗体反应。检测针对这些区域的抗体可以作为指导疫苗配方的工具,并作为监测临床试验中保护性反应发展的诊断工具。